0001610717-24-000239.txt : 20240516 0001610717-24-000239.hdr.sgml : 20240516 20240516175124 ACCESSION NUMBER: 0001610717-24-000239 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240514 FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hata Yujiro S CENTRAL INDEX KEY: 0001649119 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38915 FILM NUMBER: 24957090 MAIL ADDRESS: STREET 1: C/O XENCOR, INC. STREET 2: 111 WEST LEMON AVENUE CITY: MONROVIA STATE: CA ZIP: 91016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 4 1 form4.xml X0508 4 2024-05-14 0001676725 IDEAYA Biosciences, Inc. IDYA 0001649119 Hata Yujiro S C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 true true President and CEO true Common Stock 2024-05-14 4 M 0 56711 4.31 A 734598 D Common Stock 2024-05-14 4 S 0 54408 41.6011 D 680190 D Common Stock 2024-05-14 4 S 0 2303 41.8357 D 677887 D Common Stock 2024-05-15 4 M 0 83856 4.31 A 761743 D Common Stock 2024-05-15 4 S 0 53592 42.5741 D 708151 D Common Stock 2024-05-15 4 S 0 29761 43.4775 D 678390 D Common Stock 2024-05-15 4 S 0 503 44.1179 D 677887 D Common Stock 2024-05-16 4 M 0 34433 4.31 A 712320 D Common Stock 2024-05-16 4 S 0 30084 41.7333 D 682236 D Common Stock 2024-05-16 4 S 0 4349 42.366 D 677887 D Stock Option (right to buy) 4.31 2024-05-14 4 M 0 56711 0 D 2028-02-26 Common Stock 56711 167743 D Stock Option (right to buy) 4.31 2024-05-15 4 M 0 83856 0 D 2028-02-26 Common Stock 83856 83887 D Stock Option (right to buy) 4.31 2024-05-16 4 M 0 34433 0 D 2028-02-26 Common Stock 34433 49454 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares subject to the option are fully vested and exercisable. /s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata 2024-05-16